Dysadherin specific drug conjugates for the treatment of thyroid cancers with aggressive phenotypes | Zendy

Samuel Jang | Zendy; Xiao-Min Yu | Zendy; Celina Montemayor | Zendy; Kamal Ahmed | Zendy; Eric Weinlander | Zendy; Ricardo V. Lloyd | Zendy; Ajitha Dammalapati | Zendy; David Marshall | Zendy; James R. Prudent | Zendy; Herbert Chen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Dysadherin specific drug conjugates for the treatment of thyroid cancers with aggressive phenotypes

Author(s) -

Samuel Jang,

Xiao-Min Yu,

Celina Montemayor,

Kamal Ahmed,

Eric Weinlander,

Ricardo V. Lloyd,

Ajitha Dammalapati,

David Marshall,

James R. Prudent,

Herbert Chen

Publication year - 2017

Publication title -

oncotarget

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.373

H-Index - 127

ISSN - 1949-2553

DOI - 10.18632/oncotarget.14904

Subject(s) - thyroid , medicine , thyroid cancer , anaplastic thyroid cancer , thyroid carcinoma , cancer research , pathology , lymph node , immunohistochemistry , cancer , follicular cell

EDC1 is a novel type of antibody-drug conjugate which binds and inhibits the Na,K-ATPase on the surface of cancer cells expressing dysadherin. The purpose of this study was to determine the expression of dysadherin in different types of thyroid carcinoma, and evaluate the therapeutic potential of EDC1 for thyroid carcinomas.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research